OncoMatch/Clinical Trials/NCT06447376
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Is NCT06447376 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Siltuximab and Epcoritamab for non-hodgkin lymphoma.
Treatment: Siltuximab · Epcoritamab · Gemcitabine and oxaliplatin — The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for participants with large b-cell lymphoma (DLBCL) or follicular lymphoma (FL). Participants will receive siltuximab, prior to the injection of epcoritamab. Epcoritamab is administered in 28 day cycles for one year. After this injection, the physician will continue to watch participants for side effects and follow the condition for a minimum of 60 days.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage ANN ARBOR STAGE III, ANN ARBOR STAGE IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic antineoplastic therapy
Must have received: anti-cd20 monoclonal antibody
Lab requirements
Blood counts
hemoglobin ≥ 8g/dl (unless bone marrow involvement by lymphoma) (transfusion allowed for symptomatic participants), absolute neutrophil count ≥1000 / μl, with or without growth factor support, platelet counts ≥ 75,000 / μl (unless bone marrow involvement by lymphoma, in which case platelet counts ≥ 50,000 / µl are required)
Kidney function
estimated creatinine clearance ≥ 30 ml/min.
Liver function
ast and/or alt up to 3 times upper limit of normal (unless elevation is secondary to disease involvement of the liver, in which case up to 5 times upper limit is permitted after discussion with the principal investigator). total bilirubin up to 1.5 times upper limit of normal (unless elevation is secondary to gilbert syndrome or of non-hepatic origin).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06447376 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic antineoplastic therapy and anti-cd20 monoclonal antibody.
What disease stage is eligible?
Stage ANN ARBOR STAGE III or ANN ARBOR STAGE IV is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages